Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2023 2
2024 3
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for m dilara
Your search for M Delaram retrieved no results
Hallmarks of primary headache: part 1 - migraine.
Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G, Della Pietra A, Fan X, Garcia-Azorin D, Gazerani P, Grangeon L, Grazzi L, Hsiao FJ, Ihara K, Labastida-Ramirez A, Lange KS, Lisicki M, Marcassoli A, Montisano DA, Onan D, Onofri A, Pellesi L, Peres M, Petrušić I, Raffaelli B, Rubio-Beltran E, Straube A, Straube S, Takizawa T, Tana C, Tinelli M, Valeriani M, Vigneri S, Vuralli D, Waliszewska-Prosół M, Wang W, Wang Y, Wells-Gatnik W, Wijeratne T, Martelletti P. Raggi A, et al. J Headache Pain. 2024 Oct 31;25(1):189. doi: 10.1186/s10194-024-01889-x. J Headache Pain. 2024. PMID: 39482575 Free PMC article. Review.
Future targets for migraine treatment beyond CGRP.
Al-Hassany L, Boucherie DM, Creeney H, van Drie RWA, Farham F, Favaretto S, Gollion C, Grangeon L, Lyons H, Marschollek K, Onan D, Pensato U, Stanyer E, Waliszewska-Prosół M, Wiels W, Chen HZ, Amin FM; European Headache Federation School of Advanced Studies (EHF-SAS). Al-Hassany L, et al. J Headache Pain. 2023 Jun 28;24(1):76. doi: 10.1186/s10194-023-01567-4. J Headache Pain. 2023. PMID: 37370051 Free PMC article. Review.
The sense of stopping migraine prophylaxis.
Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K, Onan D, Pensato U, Storch E, Torrente A, Waliszewska-Prosół M, Reuter U; European Headache Federation School of Advanced Studies (EHF-SAS). Al-Hassany L, et al. J Headache Pain. 2023 Feb 16;24(1):9. doi: 10.1186/s10194-023-01539-8. J Headache Pain. 2023. PMID: 36792981 Free PMC article. Review.
Risk factors associated to disability in primary headaches: a systematic review to inform future iterations of the Global Burden of Disease Study.
Raggi A, Castaldo M, Chiang CC, Cho SJ, Chu MK, Della Pietra A, Holland PR, Husøy AK, Labastida-Ramírez A, Lytvyak E, Messina R, Onan D, Onofri A, Ornello R, Pellesi L, Petrušič I, Puledda F, Raffaelli B, Rubio-Beltrán E, Ruscheweyh R, Scuteri D, Sebastianelli G, Straube S, Tana C, Vuralli D, Waliszewska-Prosół M, Wang W, Wells-Gatnik W, Woldeamanuel YW, Wu JW, Yener SM, Corso B, Martelletti P. Raggi A, et al. J Headache Pain. 2025 Dec 23;27(1):9. doi: 10.1186/s10194-025-02233-7. J Headache Pain. 2025. PMID: 41437223 Free PMC article. Review.
Central MOTS-c infusion affects reproductive hormones in obese and non-obese rats.
Ozturk Öztürk DA, Erden Y, Tekin S. Ozturk Öztürk DA, et al. Neurosci Lett. 2024 Mar 15;826:137722. doi: 10.1016/j.neulet.2024.137722. Epub 2024 Mar 8. Neurosci Lett. 2024. PMID: 38462167
Each main group was divided into 4 subgroups (Control, Sham, 10 and 100 M MOTS-c). The lateral ventricles of the animals in the treatment groups were infused with 10 and 100 M MOTS-c (solvent in Sham group) for 14 days. ...
Each main group was divided into 4 subgroups (Control, Sham, 10 and 100 M MOTS-c). The lateral ventricles of the animals in the treat …
Treatment initiation rates of patients with positive anti-hepatitis C virus results in tertiary hospitals in Turkey.
Çelen MK, Ertürk Şengel B, Kaya Ş, Demirtürk N, Azap A, Pullukçu H, Eroğlu E, Yıldırım F, Barut HŞ, Zerdali E, Sağmak Tartar A, Mete AÖ, Şahin AM, Mutay Suntur B, Sarı ND, Yılmaz E, Candevir A, Şimşek F, İnan D, Akhan S, Asan A, Günal Ö, Ural O, Parlak M, Çabalak M, Nazik S, Hızel K, Kınıklı S, Beştepe Dursun Z, Batırel A, Mermutluoğlu Ç. Çelen MK, et al. J Infect Dev Ctries. 2024 Mar 31;18(3):441-449. doi: 10.3855/jidc.17910. J Infect Dev Ctries. 2024. PMID: 38635621 Free article.
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A. Abdul Razak AR, et al. J Clin Oncol. 2016 Dec;34(34):4142-4150. doi: 10.1200/JCO.2015.65.3949. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 26926685 Free PMC article. Clinical Trial.
The maximum-tolerated dose was defined at 65 mg/m(2) using a twice-a-week (days 1 and 3) dosing schedule. The recommended phase II dose of 35 mg/m(2) given twice a week was chosen based on better patient tolerability and no demonstrable improvement in radiologic res …
The maximum-tolerated dose was defined at 65 mg/m(2) using a twice-a-week (days 1 and 3) dosing schedule. The recommended phase II do …